Archives
Antimycin A4: ATP-Citrate Lyase Inhibitor for Metabolic Rese
Antimycin A4: Unleashing Dual Mechanistic Insights in Energy Metabolism Research
Principle Overview: Antimycin A4 as a Dual Pathway Blocker
Antimycin A4 (CAS No. 27220-59-3) is a bioactive antibiotic produced by Streptomyces species and supplied by APExBIO. It acts as a highly selective ATP-citrate lyase inhibitor, directly blocking the conversion of citrate to acetyl-CoA, a pivotal step in fatty acid and cholesterol biosynthesis. Simultaneously, Antimycin A4 disrupts the mitochondrial respiratory chain by inhibiting electron flow between cytochromes b and c₁, resulting in a rapid blockade of ATP production. This dual action makes it an indispensable energy metabolism research tool, especially for dissecting metabolic flux, modeling mitochondrial dysfunction, and evaluating antimicrobial strategies.
With a competitive inhibition constant (Ki) of 64.8 μM for ATP-citrate lyase and established efficacy in blocking eukaryotic energy metabolism, Antimycin A4 uniquely supports advanced metabolic investigations. Its solubility in DMSO, moderate molecular weight (506.55 Da), and well-characterized bioactivity profile make it suitable for in vitro, ex vivo, and select in vivo workflows, especially when precise modulation of lipid and energy pathways is required (see related review).
Step-by-Step Workflow: Protocol Enhancements for Reliable Results
Implementing Antimycin A4 in bench experiments requires attention to both its chemical stability and the biological context of use. Below we outline an optimized experimental workflow, integrating insights from product data and recent literature.
Protocol Parameters
- Stock solution preparation: Dissolve Antimycin A4 in DMSO to 10 mM; store aliquots at -20°C and avoid repeated freeze-thaws. Use within 1 month for maximal stability.
- Working concentration: For ATP-citrate lyase inhibition, employ 50–100 μM in cell culture, aligning with the reported Ki value. Adjust concentration based on cell type sensitivity and target pathway.
- Incubation conditions: Treat cells for 2–24 hours at 37°C, depending on readout (e.g., acute metabolic flux vs. chronic lipid accumulation assays).
- Solvent control: Maintain DMSO below 0.1% (v/v) in all experimental wells to avoid solvent-induced cytotoxicity.
- Harvest timing: For mitochondrial respiration studies, collect samples 4–6 hours post-treatment to capture early metabolic responses.
These parameters represent a starting point; optimization may be required for different cell lines or assay endpoints. For detailed application notes, consult the product page.
Advanced Applications and Comparative Advantages
Antimycin A4’s dual inhibitory profile unlocks sophisticated experimental designs. As an ATP-citrate lyase inhibitor, it serves as a precise fatty acid and cholesterol biosynthesis blocker, enabling researchers to model metabolic disorders, interrogate cancer cell lipid metabolism, and probe the interface between energy supply and biosynthetic demand. Its concurrent action as a mitochondrial respiratory chain inhibitor supports mitochondrial stress tests, metabolic flux measurements, and the study of apoptosis or necrosis pathways associated with impaired oxidative phosphorylation (compare mechanistic insights).
Emerging research highlights several comparative advantages of Antimycin A4:
- Metabolic Flux Dissection: Combining Antimycin A4 with isotopic tracers allows precise mapping of acetyl-CoA sources and downstream lipid pools.
- Disease Modeling: Its dual mechanism enables in vitro replication of metabolic defects observed in cancer, neurodegeneration, and metabolic syndrome (see translational guidance).
- Antibacterial and Fungicidal Assays: At concentrations matching product specifications (e.g., 3.5 μg/mL post-fermentation), Antimycin A4 delivers robust activity against sensitive bacterial and fungal strains, supporting screening of antimicrobial resistance.
Compared to single-pathway inhibitors, Antimycin A4 provides a more comprehensive metabolic blockade, facilitating systems-level studies and revealing compensatory responses not evident with narrower agents.
Key Innovation from the Reference Study
The reference study by Chen et al. (2020) introduced a copper-catalyzed tandem radical cyclization for the efficient synthesis of sulfur/nitrogen-doped fluoranthene analogs under mild conditions. The key innovation lies in leveraging radical cascade reactions to construct complex heterocyclic scaffolds with high yield and functional diversity, notably using DMSO as an optimal solvent and minimizing base requirements for cleaner reactions.
Practical translation for Antimycin A4 assays: The study’s workflow optimization—particularly the use of DMSO as a solvent and careful control of reaction temperature and catalyst loading—informs best practices when preparing Antimycin A4 solutions for biochemical assays. Researchers can adopt similar solvent and temperature handling recommendations to maximize compound stability and reproducibility, especially in high-throughput or analytical workflows where chemical integrity is paramount.
Troubleshooting & Optimization Tips
- Compound Precipitation: If Antimycin A4 precipitates upon dilution, briefly warm the stock solution to room temperature and vortex before adding to cell culture media. Avoid prolonged exposure to light and air.
- Variable Inhibition: Differences in cell line sensitivity can affect observed metabolic blockade. Titrate concentrations in pilot studies, starting at 50 μM and incrementally increasing to 150 μM as needed.
- Assay Drift due to Solvent: DMSO, while an excellent solvent for Antimycin A4, can compromise cell viability above 0.1%. Always match vehicle controls and minimize solvent exposure times, mimicking the reference study’s emphasis on solvent optimization.
- Off-Target Effects: For experiments requiring pathway specificity, use additional metabolic controls (e.g., citrate supplementation) to confirm ATP-citrate lyase dependency of observed phenotypes.
- Long-Term Storage: Follow the APExBIO product guidelines and avoid storing working solutions for more than one month; always prepare fresh dilutions before critical assays.
Interlinking: Complementary and Contrasting Resources
The landscape of Antimycin A4 research is enriched by several recent reviews and protocols:
- The article "Antimycin A4: Unlocking Metabolic Control for Translational Research" complements this guide by offering protocol parameters and strategic comparisons for translational research, emphasizing applications in disease modeling.
- "Antimycin A4: Mechanistic Insights and Emerging Roles" extends the mechanistic discussion, providing structural biology context and advanced research applications, particularly in mitochondrial dysfunction models.
- In contrast, "Antimycin A4 (SKU C8711): Reliable Dual Inhibitor for Energy Metabolism" focuses on practical laboratory challenges and Q&A-driven insights, helping troubleshoot issues in cell viability and reproducibility.
Future Outlook: Implications and Advancement
The dual-action profile of Antimycin A4 positions it at the forefront of metabolic research and translational applications. As evidenced by the recent advances in heterocyclic synthesis, workflow optimization and solvent management are increasingly critical as researchers seek to maximize reproducibility and specificity in metabolic assays. Looking ahead, Antimycin A4 is expected to play an expanding role in:
- Deciphering complex metabolic adaptations in cancer and neurodegeneration
- Accelerating screening for novel antibacterial and fungicidal agents
- Supporting high-content, systems-level interrogation of energy metabolism and biosynthetic networks
By integrating robust experimental design, attention to compound handling, and insights from recent synthetic methodologies, researchers can leverage APExBIO’s Antimycin A4 to generate reproducible, high-impact data at the interface of chemical biology and disease modeling.